INCREASING FUNCTIONALITY AND THE QUALITY OF LIFE THROUGH MEDICAL REHABILITATION IN PATIENTS WITH PARKINSON S DISEASE

Similar documents
ROLE AND IMPORTANCE OF REHABILITATION TREATMENT IN PATIENTS WITH PARKINSON S DISEASE VODA, Ioana¹; DOGARU, Gabriela¹, ²

The therapeutic benefits of natural therapeutic factors in Baile Tusnad for the rehabilitation of patients with Parkinson s disease

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Visualization and simulated animations of pathology and symptoms of Parkinson s disease

III./3.1. Movement disorders with akinetic rigid symptoms

The Parkinson s You Can t See

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

ISSUES CONCERNING THE ROLE OF PHYSIOTHERAPY IN PARKINSON S DISEASEOF PATIENTS RECOVERY

USING PRECISION MEDICINE TO HELP PATIENTS WITH PARKINSON S DISEASE. The Michael J. Fox Foundation for Parkinson s Research

Cheyenne 11/28 Neurological Disorders II. Transmissible Spongiform Encephalopathy

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Identification number: TÁMOP /1/A

UNDERSTANDING PARKINSON S AND THE POWER OF INTENT. Samantha Elandary, MA, CCC-SLP Founder & Chief Executive Officer Parkinson Voice Project

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Movement Disorders: A Brief Overview

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Basal ganglia Sujata Sofat, class of 2009

Objectives. RAIN Difficult Diagnosis 2014: A 75 year old woman with falls. Case History: First visit. Case History: First Visit

Parkinson s Disease. Sirilak yimcharoen

Parts of the motor circuits

Lecture XIII. Brain Diseases I - Parkinsonism! Brain Diseases I!

Medical Surveillance of Manganese exposed workers

Program Agenda. 11:45 AM ET Registrants Join the Program Dial-in: (877) Log-in:

Basal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

UNDERSTANDING PARKINSON S DISEASE

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Dementia. Assessing Brain Damage. Mental Status Examination

Corporate Medical Policy

Update on Parkinson s disease and other Movement Disorders October 2018

Detection of Parkinson S Disease by Speech Analysis

HYPERBARIC OXYGEN TREATMENT ON A PARKINSON S DISEASE PATIENT: A CASE STUDY Hoggard ML, Johnson KE and Shirachi DY. Chico Hyperbaric Center, Chico, CA

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Parkinson s for Care Staff

A. General features of the basal ganglia, one of our 3 major motor control centers:

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Understanding Parkinson s Disease Important information for you and your loved ones

Chapter 20. Media Directory. Amyotrophic Lateral Sclerosis. Alzheimer s Disease. Huntington s Chorea. Multiple Sclerosis

EVALUATION OF PATIENTS WITH LOWER EXTREMITY PERIPHERAL ARTERY DISEASE BY WALKING TESTS: A PILOT STUDY

What is Parkinson s disease?

Evaluation of Parkinson s Patients and Primary Care Providers

Transcranial sonography in movement disorders

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

A. General features of the basal ganglia, one of our 3 major motor control centers:

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

The contribution of transcranial sonographic examination to the diagnosis of Parkinson s disease

Kinematic Modeling in Parkinson s Disease

Can Tango Help Improve Quality of Life for Patients with Parkinson s Disease?

IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY DOCTORAL SCHOOL NEUROSCIENCE SECTION 6 28 MARCH UMF IULIU HATIEGANU CLUJ-NAPOCA ROMANIA

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

The Shaking Palsy of 1817

Nervous System Document Based Questions (DBQ)

Parkinson s UK Brain Bank

XADAGO (safinamide) oral tablet

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

National Cancer Action Team. Rehabilitation Care Pathway Poor Mobility and Loss of Function

Damage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.

Strick Lecture 4 March 29, 2006 Page 1

Appendix I (a) Human Surveillance Case Definition (Revised July 4, 2005)

Adverse outcome pathways to bridge the gap between epidemiology and experimental neurotoxicology

Parkinson s Disease. Gillian Sare

The Person: Dementia Basics

Is Safinamide Effective as an Add-on Medication in Treating Parkinson's Disease Motor Symptoms?

CRITICALLY APPRAISED PAPER (CAP)

Dystonia: Title. A real pain in the neck. in All the Wrong Places

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types

COGNITIVE IMPAIRMENT IN PARKINSON S DISEASE

who have been unresponsive to L-dopa therapy

MOVEMENT OUTLINE. The Control of Movement: Muscles! Motor Reflexes Brain Mechanisms of Movement Mirror Neurons Disorders of Movement

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

DISORDERS OF THE NERVOUS SYSTEM

netw rks Guided Reading Activity Body and Behavior Lesson 1 The Basics of the Nervous System Review Questions: Outlining

MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS

Parkinson s Disease and Its Treatment

Parkinson's Disease KP Update

The radiological, osteodesitometrical and inflammatory parameters aspects in experimentally induced chronic arthritis

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Does Resistance Training Improve Mobility in Patients with Parkinson s Disease?

The motor regulator. 1) Basal ganglia/nucleus

PD AND FALLS J U MALLYA FALLS AWARENESS MEETING

FORM ID. Patient's Personal Details. SECTION A : Medical Record of the Patient. Name. Policy Number. NRIC/Old IC/Passport/Birth Cert/Others

Continence/Constipation Workshop for RNs in Long-Term Care

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

Faculty/Presenter Disclosure

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

MOTOR NEURONE DISEASE

Exercise in Parkinson s the new drug

Schizophrenic twin. Normal twin

Transcription:

INCREASING FUNCTIONALITY AND THE QUALITY OF LIFE THROUGH MEDICAL REHABILITATION IN PATIENTS WITH PARKINSON S DISEASE Moldovan Andreea Alexandra², Dogaru Gabriela 1,2 ¹University of Medecine and Pharmacy Iuliu Hatieganu Cluj ²Rehabilitation Hospital Cluj ABSTRACT Parkinson s disease is a neurodegenerative disorder of the extrapyramidal nervous system, due to the destruction of pigmented dopaminergic neurons, particularly in the substantia nigra of the brainstem. The age range at which this symptomatology most frequently occurs is between 50 and 70 years. In Romania, incidence is 4000-5000 new cases per year, with a prevalence of 30,000-50,000 cases for the whole country. There are three major clinical symptoms: rest tremor, extrapyramidal rigidity, akinesia. Physical-kinetic treatment is extremely important, helping patients to maintain their professional and extraprofessional activities for as long as possible, improving walking disorders, hypokinesia and the flexion tendency, while being supported by adequate psychotherapy. The work techniques should be chosen depending on the clinical form and the severity of the functional deficit, as well as on the individual peculiarities of each patient.the whole medical rehabilitation program should be carried out in a peaceful, relaxing environment, taking into consideration the quality not the quantity of the exercises, while a decisive role is played by the family, which must continuously encourage and support the patient. Key Words: Parkinson s disease, medical rehabilitation, occupational therapy, kinetotherapy 193

Introduction The history of Parkinson s disease began in 1817, when James Parkinson described among motor disorders a disease termed shaking palsy, which was later named after him. This is a neurodegenerative disease of the extrapyramidal nervous system, due to the destruction of pigmented dopaminergic neurons, particularly in the substantia nigra of the brainstem. This degeneration leads to a dopamine deficiency in the striatal projection areas of these neurons. In 1912, the presence of characteristic hyaline inclusions, which were subsequently termed Lewy bodies, was also found. The age range at which the symptomatology of Parkinson s disease most frequently occurs is between 50 and 70 years. These symptoms become manifest when 70-80% of striatal dopaminergic neurons and 50% of nigral dopaminergic neurons are lost. The disease frequency is considerable, with a 1:40,000 prevalence in the general population, while in the population aged over 40 years, prevalence is 1:200, with a predominance in the male sex, 1.25:1; only 5-15% of the cases are accounted for by heredity. In Romania, incidence is 4000-5000 new cases per year, with a prevalence of 30,000-50,000 cases for the whole country. Although idiopathic Parkinson s disease is usually sporadic, the genetic component of the disease has also been discussed. A major finding of recent years is the mapping and cloning of several genes that cause the single gene transmission forms of the disease. However, these seem responsible for the disease in a relatively small number of families, and the genetic substrate of the majority of the cases has no clear pattern [1]. The role of environmental factors in the etiology of Parkinson s disease is not certain, but in the course of time, correlations between the disease and several factors such as steel industry, agriculture, pesticide exposure, paper and wood industry have been established. The repeated exposure to an environmental toxin might explain the age range at which the disease occurs [4]. Studies performed on monozygotic and dizygotic twins have suggested that the disease rarely has a genetic basis. Positron emission tomography has shown that asymptomatic twins frequently have striatal dopamine uptake anomalies. The spread of encephalitis lethargica (sleep disease) throughout the world in the 1920 s led to parkinsonism in 80% of these patients. However, there is a difference between postencephalic parkinsonism and Parkinson s disease; the subjects of the first category do not have Lewy bodies in the substantia nigra. Other studies have failed to prove an association between a virus and Parkinson s disease [2, 3]. During dopamine oxidation, toxic free oxygen radicals are produced. Oxidative stress leads to increased iron concentrations, low glutathione and peroxidase levels, while the activity of MAO-B (a dopamine mediator) tends to increase with age. Cranial trauma in the pathogenesis of the disease is debatable, and so is the location of newly formed lesions in the structures responsible for the development of Parkinson s syndrome. It has been demonstrated that vascular factors such as arterial hypertension can favor Parkinson s disease [4]. Parkinson s disease is dominated by three major symptoms: rest tremor, extrapyramidal rigidity, akinesia. Starting from the hypothesis that medical rehabilitation treatment is indispensable to the therapeutic program in Parkinson s disease, its effectiveness was studied in order to increase the functionality and the quality of life of patients with Parkinson s disease. Physical-kinetic treatment is extremely important, helping patients to maintain their 194

professional and extraprofessional activities for as long as possible, improving walking disorders, hypokinesia and the flexion tendency, while being supported by adequate psychotherapy. The work techniques should be chosen depending on the clinical form and the severity of functional deficit, as well as on the individual peculiarities of each patient. Treatment should be initiated since the onset of the disease, and in the fully established disease, it will be related to the effectiveness of drug therapy. In the on period, therapy is limited to increasing the speed of movement execution and coordination, while in the off period, the patient must attend a functional program, being incapable of exercise. The participation in the rehabilitation program is determined by the patient s confidence in the therapist. The entire program should be carried out in a peaceful, relaxing environment, taking into consideration the quality, not the quantity of exercises, while a decisive role is played by the family, which should continuously understand, encourage and support the patient [5, 6]. Material and method The study was performed in the Clinical Rehabilitation Hospital Cluj- Napoca, in the Clinical Rehabilitation Hospital Băile Felix, as well as in the Clinical Emergency Hospital Cluj-Napoca, Department of Neurology, in the period April-May 2014. The study included 20 patients with Parkinson s disease, of which 14 men and 6 women, patients with stages 1, 2 and 3 of the disease. Ten of these received anti-parkinson drug therapy (group B), and the other 10 received in addition to drug therapy, individualized rehabilitation treatment for two weeks (group A). The rehabilitation program consisted of kinetotherapy (active mobilizations, recovery of initiative and walking speed, recovery of grip, respiratory gymnastics, facial expression exercises, exercises for pelvic muscle toning, recovery of transfers, recovery of balance), occupational therapy, medical massage, magnetodiaflux, medium frequency interferential currents. The Barthel scale was used for the evaluation of 10 items: walking, transfer, climbing stairs, feeding, hygiene, dressing, toilet use, continence, micturitions, bathroom use before and after medical rehabilitation treatment. The results were graphically recorded, based on analytical tables. The data obtained were processed in Microsoft Excel, using the Student test for paired samples. We used the Barthel index to measure the degree of independence and performance in activities of daily life, with the aim of increasing the quality of life of patients, their functionality and independence. The exclusion criteria of this study were contraindications of physiokinetotherapy due to associated pathology or refusal of the patient. Results and discussion 1. Analysis of the groups depending on sex distribution This study shows that Parkinson s disease was more frequent in the male sex, in a proportion of 65%, which is in accordance with the literature data. 2. Analysis of the groups depending on age decades In the evaluated groups, the age limits ranged between 50 and 81 years, with a mean age of 60 years. 195

accompanied by muscle pain was seen in 6 patients (30%), and bradykinesia in 3 patients (15%) [Diagram 4]. Diagram 2 shows the distribution of all studied patients depending on age, in order to monitor the disease frequency from this point of view. The highest incidence of Parkinson s disease was found for decades 7 and 8, i.e. between 60 and 79 years, while there were two patients (10%) in decade 6 and another two patients in decade 9. 3. Analysis of the groups depending on the patient s occupation Of all patients, 2 (10%) continued to be active, and the rest of 18, i.e. 90% of them were retired due to advanced age and to the disease that limited effective work. The pursued aim is to help patients with working potential to maintain their professional activities for as long as possible. 5. Graphical representation depending on the improvement of walking In order to calculate the degree of walking independence at admission, we used the Barthel scale. We concluded that of the 20 patients, only 8 (40%) were completely independent, 9 (45%) required a certain degree of assistance for walking, and 3 (15%) were completely dependent on their entourage [Diagram 5]. The aim of walking reeducation was to improve balance, the patients ability to walk alone, and to diminish the risk of fall, in order to increase functionality and the quality of life of these patients. 4. Graphical representation depending on the onset symptom of the disease Following analysis, it was found that the predominant onset symptom was tremor in 11 patients (55%), while rigidity 196

of patients who received drug therapy, only 60% of patients had improvements, the rest of 40% having the same difficulties regarding feeding. 7. Distribution of patients depending on the improvement of micturition and incontinence Patients of this study had sphincter incontinence and imperative micturition before treatment. The analysis of the diagram shows that patients of group A, who attended a rehabilitation program, had an improvement in walking, while patients of group B had no improvement. Statistically, 20% of group A patients were initially dependent, 50% required a certain degree of assistance, and 30% were independent; after discharge, the percentage of dependent patients decreased to 10%, the proportion of patients requiring a certain degree of assistance decreased to 40%, and the number of independent patients increased to 50%. It can be seen that after drug treatment, the percentages of all patient categories in group B were unchanged [Diagram 6]. 6. Graphical representation depending on the improvement of feeding Based on Diagram 8, it can be concluded that all patients of group A had a certain improvement of incontinence or laborious micturition after treatment. In group B, patients who received drug therapy alone had fewer improvements after day 10 of treatment. Statistically, only 60% of patients in group B had improvements, the rest of 40% of group B patients showing no improvement, while 100% of group A patients had improvements. 8. Distribution of patients depending on their degree of dependence in carrying out activities of daily life using the Barthel index The analysis of Diagram 7 clearly shows that patients of the study group A had a greater number of improvements regarding feeding and the degree of dependence related to it. In group A, 90% of patients had improvements, while in group B, the group 197

The analysis of Diagram 9 evidences small improvements in the degree of dependence of group B patients, according to the Barthel scale, but significant improvements can be seen in group A patients, who received rehabilitation treatment in addition to drug therapy. The benefits of physiokinetotherapy in reducing the degree of dependence in patients with Parkinson s disease are obvious. From a statistical point of view, 80% of patients of group A had improvements in functionality and implicitly, in the quality of life, while only 40% of patients of group B had improvements. CONCLUSIONS The study group, including patients who attended a physical-kinetic program in addition to drug treatment, had 80% increases in functionality and implicitly, in the quality of life, while in the control group, only half of these improvements were found after drug therapy alone. Kinetotherapy considerably improved walking, reducing the degree of dependence in patients of the study group. Occupational therapy significantly contributed to increasing the patients performance in carrying out activities of daily life. The use of individualized physicalkinetic techniques for each patient allowed to improve their condition. Patients who attended a rehabilitation program know maintenance exercises that they will be able to perform at home for at least 30 minutes every day, and their families know the details of how to make the patient s life easier. Bibliography 1. http://educatie-fizicakineto/pdf/studenti/cursuri%master/note _curs_nervos.pdf 2. Lăcrimioara Perju-Dumbravă. Strategii terapeutice moderne în Boala Parkinson. Cluj-Napoca: Editura Medicală Universitară Iuliu Hațieganu ; 2002. p. 29-79. 3. Marilena Kory-Mercea, țtefania Kory Calomfirescu. Kinetoterapia pacienților cu Boală Parkinson. Cluj-Napoca: Editura Risoprint; 2009. 4. www.uni.edu/walsh/balsalganglia-2.ipg 5. Roger C. Duvoisin, M.D. Parkinson s disease. A guide for Patient and Family. 3th ed. New York: Raven Press; 1991.Schapira A.H.W. Progress in Parkinson s disease. New York: Raven Press; 2003. 198